Search Articles
Boston Scientific lost billions of dollars in market value because its directors misrepresented its defibrillator business, shareholders claim in a derivative complaint in Boston Federal Court.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.